Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05762055
Other study ID # STU-2022-1092
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 5, 2024
Est. completion date May 2026

Study information

Verified date March 2024
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study team will plan a prospective, randomized control trial using our institution's spine clinical outcomes registry. Eligible patients undergoing ACDF (see inclusion criteria listed below) will be randomized to an Intervention or Control Group, which will differ according to the interbody cage used during the procedure. In the Intervention Group (100 patients), Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted at each treated level. In the Control Group (100 patients), patients will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology. Interbody cages used in the Control Group (along with the decision to apply anterior plate fixation) will be determined according to surgeon preference. There will be no blinding to the type of implant used. Standard demographic and procedural variables will be collected for all patients (including history of diabetes, tobacco, use, prior use of oral corticosteroids, number of levels fused, and presence of bicortical screw placement). Clinical and radiographic outcomes in the Intervention and Control Groups will be directly compared.


Description:

Aim 1: Examine the effect of nanoLOCK technology on rates of postoperative dysphagia after ACDF. Aim 2: Evaluate the effect of nanoLOCK technology on radiographic fusion. Aim 3: Evaluate how nanoLOCK technology influences the development of radiographic adjacent segment disease.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date May 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Subjects 18 years of age or older - Subjects undergoing ACDF surgery for degenerative pathology (one, two or three levels) - Subjects with no prior history of cervical spine surgery - Subjects with complete/usable data Exclusion Criteria: - Subjects under the age of 18 - Subjects not undergoing ACDF surgery - Subjects with prior cervical spine surgery - Subjects with cervical neoplastic or infectious disease pathology - Subjects with cervical trauma pathology - ACDF performed at C2-3 - Subjects with incomplete/unusable data

Study Design


Intervention

Device:
Titan nanoLOCK interbody cage
Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
ACDF interbody cage
Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology

Locations

Country Name City State
United States University of Texas Southwestern Medical Center Dallas Texas

Sponsors (2)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient reported dysphagia events measured by Eat-10 assessment tool Number of patient reported dysphagia events (incidence & severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. Postoperative at Day 1
Primary Number of patient reported dysphagia events measured by Eat-10 assessment tool Number of patient reported dysphagia events (incidence & severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. 2 weeks following surgery
Primary Number of patient reported dysphagia events measured by Eat-10 assessment tool Number of patient reported dysphagia events (incidence & severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. 3 months following surgery
Primary Number of patient reported dysphagia events measured by Eat-10 assessment tool Number of patient reported dysphagia events (incidence & severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. 6 months following surgery
Primary Number of patient reported dysphagia events measured by Eat-10 assessment tool Number of patient reported dysphagia events (incidence & severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. 12 months following surgery
Primary Dysphagia as measured by SWAL-QOL assessment tool Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best). Postoperative at day 1
Primary Dysphagia as measured by SWAL-QOL assessment tool Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best). 2 weeks following surgery
Primary Dysphagia as measured by SWAL-QOL assessment tool Dysphagia is measured by SWAL-QOL assessment tool which is used in understanding quality of life in swallowing disorders. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best). 3 months following surgery
Primary Dysphagia as measured by SWAL-QOL assessment tool Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best). 6 months following surgery
Primary Dysphagia as measured by SWAL-QOL assessment tool Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best). 12 months following surgery
Primary Degree of radiographic fusion Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine. 6 weeks following surgery
Primary Degree of radiographic fusion Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine. 3 months following surgery
Primary Degree of radiographic fusion Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine. 6 months following surgery
Primary Degree of radiographic fusion Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine. 12 months following surgery
Primary Incidence of radiographic adjacent segment disease Incidence of radiographic adjacent segment disease is measured by quantifying (number of occurrence) the following parameters (i.e., Suprajacent and/or subjacent level kyphosis; Vacuum disc phenomenon at adjacent level discs; Adjacent level compression deformity) on postoperative imaging 6 months following surgery
Primary Incidence of radiographic adjacent segment disease Incidence of radiographic adjacent segment disease is measured by quantifying (number of occurrence) the following parameters (i.e., Suprajacent and/or subjacent level kyphosis; Vacuum disc phenomenon at adjacent level discs; Adjacent level compression deformity) on postoperative imaging 12 months following surgery
Secondary Percentage of participants experiencing neck pain Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable. Baseline (Pre-op)
Secondary Percentage of participants experiencing neck pain Percentage of participants experiencing neck pain is assessed using Vissual Analogue Scale (VAS)-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable. 6 weeks following surgery
Secondary Percentage of participants experiencing neck pain Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable. 3 months following surgery
Secondary Percentage of participants experiencing neck pain Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable. 6 months following surgery
Secondary Percentage of participants experiencing neck pain Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable. 12 months following surgery
Secondary Percentage of participants showing functional improvement Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. Baseline (Pre-op)
Secondary Percentage of participants showing functional improvement Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. 6 weeks following surgery
Secondary Percentage of participants showing functional improvement Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. 3 months following surgery
Secondary Percentage of participants showing functional improvement Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. 6 months following surgery
Secondary Percentage of participants showing functional improvement Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. 12 months following surgery
Secondary Number of participants who experienced overall complications Overall complication rate is measured by number of participants who experienced overall complications (including instrumentation fracture, cage subsidence, revision surgery, and wound breakdown/infection) 3 years following surgery
Secondary Percentage of participants reporting functional outcomes as measured by PROMIS-29 Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score). Baseline (Pre-op)
Secondary Percentage of participants reporting functional outcomes as measured by PROMIS-29 Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score). 6 weeks following surgery
Secondary Percentage of participants reporting functional outcomes as measured by PROMIS-29 Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score). 3 months following surgery
Secondary Percentage of participants reporting functional outcomes as measured by PROMIS-29 Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score). 6 months following surgery
Secondary Percentage of participants reporting functional outcomes as measured by PROMIS-29 Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score). 12 months following surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06102304 - Myo-Electrical and Nerve Root Function Response to Focused Extracorpeal Shock Wave in Cervical Radiculopathy N/A
Recruiting NCT06220799 - Impact of Craniovertebral Angle on Dizziness and Risk of Falling in Cervical Radiculopathy Patients
Completed NCT01944150 - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis N/A
Recruiting NCT01495728 - Thoracic Manipulation in Patients With Cervical Radiculopathy N/A
Active, not recruiting NCT00695006 - Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT N/A
Completed NCT00344890 - Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy N/A
Completed NCT03382821 - Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach Phase 4
Completed NCT04915222 - Manual Cervical Traction and Natural Apophyseal Glides for Cervical Radiculopathy Patients N/A
Recruiting NCT06040047 - Prediction of Cervical Radiculopathy Success With PNF and Mobilization N/A
Recruiting NCT06043934 - Neural Mobilization With Intermittent Cervical Traction on Grip Strength, Sleep Quality, and Quality of Life in Cervical Radiculopathy N/A
Completed NCT04544683 - Effectiveness of Cervical Transforaminal Epidural Steroid Injection Phase 4
Active, not recruiting NCT03674619 - Cervical Radiculopathy Trial N/A
Completed NCT04597112 - Effect of Myofascial Release Technique In Patients With Unilateral Cervical Radiculopathy N/A
Completed NCT04598113 - Effect of Cervical Traction on Balance in Cervical Radiculopathy Patients N/A
Recruiting NCT06339970 - Effects of Slider Versus Tensioners Nerve Gliding in Cervical Radiculopathy. N/A
Withdrawn NCT02694250 - Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw N/A
Completed NCT02081456 - Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain N/A
Terminated NCT00308594 - Oral Dexamethasone for the Treatment of Cervical Radiculopathy Phase 2
Completed NCT05887427 - Acute Effect of Neural Mobilization in Cervical Radiculopathy: A Randomized Controlled Study N/A
Completed NCT05852613 - Effect of HPLT on Pain and Electrophysiological Study in Cervical Radiculopathy Patients Phase 3